Cintia Cercato

Cintia Cercato

Auto-generated profile, based on publicly available information

Cintia Cercato

Brazilian Association of Study on Obesity and Metabolic Syndrome ABESO São Paulo Brazil

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DRDonna H Ryan
Donna H Ryan
ILIldiko Lingvay
Ildiko Lingvay
JDJohn Deanfield
John Deanfield
SKSteven E. Kahn
Steven E. Kahn
Eric BarrosEric Barros
Eric Barros
RKRobert F. Kushner
Robert F. Kushner
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m−2) there were lower rates (events per 100 years of observation) of serious adverse events with semaglutide (43.23, 43.54, 51.07 and 47.06 for semaglutide and 50.48, 49.66, 52.73 and 60.85 for placebo). Semaglutide was associated with increased rates of trial product discontinuation. Discontinuations increased as BMI class decreased. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years. ClinicalTrials.gov identifier: NCT03574597.

30 June 2009 in International Journal of Obesity
Verified
Journal Article
Closed access
CCC Cercato
C Cercato
VRV A Roizenblatt
V A Roizenblatt
CLC C Leança
C C Leança
ASA Segal
A Segal
AFA P Lopes Filho
A P Lopes Filho
AHA Halpern
A Halpern

7 December 2023 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
RMRodrigo Oliveira Moreira
Rodrigo Oliveira Moreira
CVCynthia Melissa Valerio
Cynthia Melissa Valerio
CVCristiane Villela-Nogueira
Cristiane Villela-Nogueira
CCCintia Cercato
Cintia Cercato
Fernando GerchmanFernando Gerchman
Fernando Gerchman
COClaudia Oliveira
Claudia Oliveira
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In this context, a panel of experts from three medical societies was organized to develop an evidence-based guideline on the screening, diagnosis, treatment, and follow-up of MASLD. Material and methods: A MEDLINE search was performed to identify randomized clinical trials, meta-analyses, cohort studies, observational studies, and other relevant studies on [...] ABSTRACT Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In this context, a panel of experts from three medical societies was organized to develop an evidence-based guideline on the screening, diagnosis, treatment, and follow-up of MASLD. Material and methods: A MEDLINE search was performed to identify randomized clinical trials, meta-analyses, cohort studies, observational studies, and other relevant studies on

19 April 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
BHBruno Halpern
Bruno Halpern
MMMarcio Corrêa Mancini
Marcio Corrêa Mancini
MMMARIA EDNA DE MELO
MARIA EDNA DE MELO
RLRodrigo N. Lamounier
Rodrigo N. Lamounier
RMRodrigo O. Moreira
Rodrigo O. Moreira
CBCesar Luiz Boguszewski
Cesar Luiz Boguszewski
Obesity is a chronic disease associated with impaired physical and mental health. A widespread view in the treatment of obesity is that the goal is to normalize the individual’s body mass index (BMI). However, a modest weight loss (usually above 5%) is already associated with clinical improvement, while weight losses of 10%-15% bring even further benefits, independent from the final BMI. The percentage of weight reduction is accepted as a treatment goal since a greater decrease in weight is [...] ABSTRACT Obesity is a chronic disease associated with impaired physical and mental health. A widespread view in the treatment of obesity is that the goal is to normalize the individual’s body mass index (BMI). However, a modest weight loss (usually above 5%) is already associated with clinical improvement, while weight losses of 10%-15% bring even further benefits, independent from the final BMI. The percentage of weight reduction is accepted as a treatment goal since a greater decrease in weight is

Verified
Journal Article
Open access
PDF file
MPMarina B. Pioltine
Marina B. Pioltine
MMMARIA EDNA DE MELO
MARIA EDNA DE MELO
ASAritania Santos
Aritania Santos
AMAlisson Machado
Alisson Machado
AFAriana E. Fernandes
Ariana E. Fernandes
MMMarcio Corrêa Mancini
Marcio Corrêa Mancini
Childhood obesity is a major public health problem. It has a direct impact on the quality of life of children and adolescents, as well as on their future risk of developing chronic diseases. Dietary patterns rich in fats and sugars and lacking dietary fibers, vitamins, and minerals, as well as lack of physical exercise have been associated with the rise of obesity prevalence. However, factors that contribute to the preference for foods rich in these nutrients are not well established. Taste is recognized as an important predictor of food choices, and polymorphisms in taste-related genes may explain the variability of taste preference and food intake. The aim of this research is to evaluate the influence of polymorphisms of the sweet taste receptor gene TAS1R2 on diet and metabolic profile in obese children and adolescents. A cross-sectional study with 513 obese children and adolescents and 135 normal-weight children was carried out. A molecular study was performed for the single nucleotide polymorphisms (SNPs) rs9701796 and rs35874116 of TAS1R2, and dietary intake, anthropometric parameters (weight, height, waist circumference, waist-to-height ratio (WHtR)), and metabolic profile (including fasting glucose, insulin, triglyceride, high-density lipoprotein (HDL)–cholesterol, and leptin levels) were analyzed. The variant rs9701796 was associated with increased waist-height ratio, as well as with a higher chocolate powder intake in obese children. The variant rs35874116 was associated with a lower dietary fiber intake. In conclusion, there was no relationship between genotypes and risk of obesity. Obese adolescents carrying the serine allele of SNP rs9701796 in TAS1R2 showed higher waist-to-height ratio and chocolate powder intake, whereas those carrying the valine allele of SNP rs35874116 in TAS1R2 were characterized by lower dietary fiber intake.

27 July 2010 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BHBruno Halpern
Bruno Halpern
EOEduardo S. L. Oliveira
Eduardo S. L. Oliveira
AFAndré M. Faria
André M. Faria
AHAlfredo Halpern
Alfredo Halpern
MMMARIA EDNA DE MELO
MARIA EDNA DE MELO
MMMarcio Corrêa Mancini
Marcio Corrêa Mancini
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry.